Clinical and Hemodynamic Outcomes in Patients with Chronic Venous Insufficiency After Oral Micronized Flavonoid Therapy

Vascular and Endovascular Surgery

Volumn 35, Issue 6, 2001, Pages 443-447

  Ting, Albert C W ^a   Cheng, Stephen W K ^a   wu, Lisa L H ^a   Cheung, Grace C Y ^b  

^a Queen Mary Hospital ^*

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

DAFLON; FLAVONOID;

ADULT; AGED; ARTICLE; CHRONIC VEIN INSUFFICIENCY; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HEART EJECTION FRACTION; HEMODYNAMICS; HUMAN; MALE; OUTCOMES RESEARCH; PAIN; PLETHYSMOGRAPHY; VEIN BLOOD FLOW;

ADULT; AGED; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; DIOSMIN; FEMALE; FLAVONOIDS; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; PLETHYSMOGRAPHY; VENOUS INSUFFICIENCY;

EID: 0035174899     PISSN: 15385744     EISSN: None     Source Type: Journal    
DOI: 10.1177/153857440103500604     Document Type: Article

References (16)

1. Biland L, Widmer LK: Varicose veins and chronic venous insufficiency: Medical and socioeconomic aspects, Basle study. Acta Chir Scand 544: 9-11, 1988.
2. Madar G, Widmer LK, Zemp E, et al: Varicose veins and chronic venous insufficiency-a disorder or a disease? A critical epidemiological review. Vasa 15: 126-134, 1986.
3. Struckmann JR, Nicolaides AN: Flavonoids: A review of the pharmacology and therapeutic efficacy of Daflon 500 mg in patients with chronic venous insufficiency and related disorders. Angiology 45: 419-428, 1994.
4. Porter JM, Moneta GL, Beebe HG, et al: Reporting standards in venous disease: An update. J Vasc Surg 21: 635-645, 1995.
5. Christopoulos D, Nicolaides AN, Szendro G, et al: Air plethysmography and the effects of elastic compression on venous haemodynamics of the leg. J Vasc Surg 5: 148-159, 1987.
6. Guilhou JJ, Fevrier F, Debure C, et al: Benefit of a 2-month treatment with a micronized, purified flavonoidic fraction on venous ulcer healing. A randomized, double-blind, controlled versus placebo trial. Int J Microcirc Clin Exp 17(suppl 1):21-26, 1997.
7. Leprond L: Action of Daflon 500 mg on the principal inflammatory mediators. Phlebology 9(suppl 1):34-39, 1994.
8. Jean T, Bodinier MC: Mediators involved in inflammation: Effects of Daflon 500 mg on their release. Angiology 45: 554-559, 1994.
9. Friesenecker B, Tsai AG, Intaglietta M: Cellular basis of inflammation, edema and the activity of Daflon 500 mg. Int J Microcirc Clin Exp 15(suppl 1):17-21, 1995.
10. Christopoulos D, Nicolaides AN, Szendro G: Venous reflux: Quantification and correlation with the clinical severity of chronic venous disease. Br J Surg 75: 352-356, 1988.
11. Welkie JF, Comerota AJ, Katz ML, et al: Hemody Ting Oral Micronized Flavonoid Therapy 447 namic deterioration in chronic venous disease. J Vasc Surg 16: 733-740, 1992.
12. Tsouderos Y: Are the phlebotonic properties shown in clinical pharmacology predictive of a therapeutic benefit in chronic venous insufficiency? Int Angiol 8(suppl 4):53-59, 1989.
13. Laurent R., Gilly R, Frileux C: Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg. Int Angiol 7(suppl 2):39-43, 1988.
14. Cospite M, Dominici A: Double-blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronised form. Int Angiol 8(suppl 4):61-65, 1989.
15. Geroulakos G, Nicolaides AN: Controlled studies of Daflon 500 mg in chronic venous insufficiency. Angiology 45: 549-553, 1994.
16. Meyer OC: Safety and security of Daflon 500 mg in venous insufficiency and in hemorrhoidal disease. Angiology 45: 579-584, 1994.